Format

Send to

Choose Destination
See comment in PubMed Commons below
Leukemia. 2010 Sep;24(9):1545-54. doi: 10.1038/leu.2010.143. Epub 2010 Jun 24.

Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.

Author information

1
Department of Medicine, Division of Hematology/Oncology, University of Massachusetts Medical School, Worcester, MA 01605, USA.

Abstract

Inhibition of BCR-ABL with kinase inhibitors in the treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) is highly effective in controlling but not curing the disease. This is largely due to the inability of these kinase inhibitors to kill leukemia stem cells (LSCs) responsible for disease relapse. This stem cell resistance is not associated with the BCR-ABL kinase domain mutations resistant to kinase inhibitors. Development of curative therapies for CML requires the identification of crucial molecular pathways responsible for the survival and self-renewal of LSCs. In this review, we will discuss our current understanding of these crucial molecular pathways in LSCs and the available therapeutic strategies for targeting these stem cells in CML.

PMID:
20574455
PMCID:
PMC3130198
DOI:
10.1038/leu.2010.143
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center